Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen-Induced Allergic Rhinoconjunctivitis

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1537-1546

  Valovirta, Erkka ^a   Berstad, Aud Katrine Herland ^b   de Blic, Jacques ^c   Bufe, Albrecht ^d   Eng, Peter ^e   Halken, Susanne ^f   Ojeda, Pedro ^g   Roberts, Graham ^h   Tommerup, Lene ⁱ   Varga, Eva Maria ^j   Winnergard, Inger ^k  

^a Suomen Terveystalo Allergy Clinic   (Finland)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d NETSTAP Forschung   (Germany)

^e Children's Hospital Aarau and Lucerne   (Switzerland)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g Clínica Subiza de Asma y Alergia   (Spain)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ ALK ABELLÓ   (Denmark)

^j MEDICAL UNIVERSITY OF GRAZ   (Austria)

^k Paediatric Outpatient Clinic   (Sweden)

more..

Author keywords

Allergy; Asthma; Grass; Immunotherapy; Prevention; Tablet

Indexed keywords

BUDESONIDE; DESLORATADINE; FLUTICASONE; GRASS POLLEN VACCINE; LORATADINE; OLOPATADINE; PREDNISOLONE; SALBUTAMOL;

ALLERGIC ASTHMA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GRASS POLLEN; HAY FEVER; HUMAN; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STANDARDIZATION; STUDY DESIGN; SUBLINGUAL IMMUNOTHERAPY;

ASTHMA; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; HUMANS; POACEAE; RHINITIS, ALLERGIC, SEASONAL; TABLETS;

EID: 80054887682     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.013     Document Type: Article

References (41)

1. Global Strategy for Asthma Management and Prevention 2008, Global Initiative for Asthma (GINA), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md, NIH publication no. 02-3659.
2. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478. Global Initiative for Asthma (GINA) Program.
3. Bacharier L.B., Boner A., Carlsen K.H., et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008, 63:5-34.
4. Passalacqua G., Ciprandi G., Canonica G.W. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001, 1:7-13.
5. Cruz A.A. The 'united airways' require an holistic approach to management. Allergy 2005, 60:871-874.
6. Compalati E., Ridolo E., Passalacqua G., et al. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol 2010, 6:413-423.
7. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
8. Demoly P., Bousquet P.J. Links between allergic rhinitis and asthma still reinforced. Allergy 2008, 63:251-254.
9. Burgess J.A., Walters E.H., Byrnes G.B., et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol 2007, 120:863-869.
10. Shaaban R., Zureik M., Soussan D., et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008, 372:1049-1057.
11. Rochat M.K., Illi S., Ege M.J., et al. Allergic rhinitis as a predictor for wheezing onset in school-aged children. J Allergy Clin Immunol 2010, 126:1170-1175.
12. Fiocchi A., Fox A.T. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed 2011, 96:91-100.
13. Jacobsen L., Niggemann B., Dreborg S., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943-948.
14. Niggemann B., Jacobsen L., Dreborg S., et al. Five-year follow up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006, 61:855-859.
15. Moller C., Dreborg S., Ferdousi H.A., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002, 109:251-256.
16. Marogna M., Tomassetti D., Bernasconi A., et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008, 101:206-211.
17. Novembre E., Galli E., Landi F., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
18. Eng P.A., Borer-Reinhold M., Heijnen I.A., Gnehm H.P. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198-201.
19. Bufe A., Roberts G. Specific immunotherapy in children. Clin Exp Allergy 2011, 41:1256-1262.
20. Canonica G.W., Passalacqua G. Disease-modifying effect and economic implications of sublingual immunotherapy. J Allergy Clin Immunol 2011, 127:44-45.
21. Canonica G.W., Baena-Cagnani C.E., Bousquet J., et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for Respiratory allergy. A statement of the World Allergy Organization (WAO) taskforce. Allergy 2007, 62:317-324.
22. Eichler I., Soriano E.S. Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children. Allergy 2011, 66:999-1004.
23. Dahl R., Kapp A., Colombo G., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 118:434-440.
24. Bufe A., Eberle P., Franke-Beckmann E., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009, 123:167-173.
25. Nelson H.S., Nolte H., Creticos P., et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80.
26. Blaiss M., Maloney J., Nolte H., et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011, 127:64-71.
27. Didier A., Malling H., Worm M., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338-1345.
28. Wahn U., Tabar A., Kuna P., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009, 123:160-166.
29. Durham S., Emminger W., Kapp A., et al. Disease-modifying effect of the SQ-standardised grass allergy immunotherapy tablet is sustained 2 years after treatment. Allergy 2010, 65:689-690.
30. Frølund L., Durham S.R., Calderon M., et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010, 65:753-757.
31. Guideline on the clinical development on products for specific immunotherapy for the treatment of allergic diseases European Medicines Agency (EMEA), CHMP/EWP/18504/2006. Published November 20, 2008, Accessed September 12, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf.
32. Note for guidance on the clinical investigation of medicinal products in the treatment of asthma European Medicines Agency (EMEA), CPMP/EWP/2922/01. Published November 21, 2002, Accessed September 12, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003555.pdf.
33. Global strategy for asthma management and prevention Global Initiative for Asthma (GINA), Updated 2010, Accessed September 12, 2010. http://www.ginasthma.org/.
34. Radulovic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010, 12. CD002893.
35. Penagos M., Passalacqua G., Compalati E., et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008, 133:599-609.
36. Calderon M.A., Alves B., Jacobson M., et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1. CD001936.
37. 2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.
38. ICH Topic E9 Statistical Principles for Clinical Trials European Medicines Agency (EMEA), CPMP/ICH/363/96. Published September 1998, Accessed September 12, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf.
39. Points to consider on multiplicity issues in clinical trials European Medicines Agency (EMEA), CPMP/EWP/908/99, Accessed September 12, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf.
40. Points to consider on missing data European Medicines Agency (EMEA), CPMP/EWP/1776/99. Published November 15, 2001, Accessed September 12, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003641.pdf.
41. Nathan R.A., Sorkness C.A., Kosinski M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004, 113:59-65.